Rising asbestos diseases in China highlight a need for worker protection.

Summary

Asbestos exposure remains a serious health issue in China. Between 1990 and 2023, the total number of people suffering from asbestos-related diseases grew continuously. These conditions include asbestosis, which is a chronic lung disease caused by inhaling asbestos fibers, as well as several types of cancer linked to the toxic material.

When looking at rates adjusted for population age and size, the historical picture is complex. The rates of new asbestosis cases peaked back in 2001, while cancers caused by asbestos reached their highest levels around 2010 and 2011. Men have consistently faced a heavier toll from these diseases than women. Notably, researchers found a specific spike in mesothelioma, a rare and aggressive cancer linked to asbestos, among men aged 55 to 59.

Although the adjusted rates saw historical declines after those peaks, mathematical models point to a troubling reversal. Between 2020 and 2022, there was an increase in deaths and disability-adjusted life years, a metric that measures years of healthy life lost to illness. It is important to note that these findings rely on statistical models from a global health database rather than direct medical records from clinics, meaning the recent uptick is based on mathematical projections rather than primary patient data.

Why it matters.

This research sounds an alarm for public health officials and policymakers. Because asbestos-related illnesses can take decades to develop, workers exposed years or even decades ago are only now facing severe health crises. The modeled spike in deaths and illness from 2020 to 2022 suggests that current safety measures and historical regulations might not be enough to protect the aging industrial workforce.

For the global medical and labor communities, these numbers highlight an urgent need for stronger workplace protection laws and better asbestos control policies. If this mathematical trend translates into packed hospital wards, the healthcare system will face a heavy burden of chronic lung diseases and complex cancers. Catching this trend early allows governments and health organizations to prepare better screening programs and strictly enforce occupational safety rules before more lives are lost.

From the source

The story in numbers.

Study timeframe for GBD data analysis: 1990-2023
Age demographic carrying the greatest disease burden: ≥65 years
Period showing a statistically modeled increase in mortality and DALYs: 2020-2022

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Rising asbestos diseases in China highlight a need for worker protection.

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.